Yahoo
OTC Markets OTCQB - Delayed Quote USD

CV Sciences, Inc. (CVSI)

0.0199 -0.0001 (-0.50%)
At close: September 2 at 3:36:35 PM EDT
Chart Range Bar
Loading chart for CVSI
  • Previous Close 0.0200
  • Open 0.0181
  • Bid 0.0181 x 1000000
  • Ask 0.0199 x 1000000
  • Day's Range 0.0180 - 0.0199
  • 52 Week Range 0.0100 - 0.1000
  • Volume 73,830
  • Avg. Volume 659,598
  • Market Cap (intraday) 4.494M
  • Beta (5Y Monthly) 0.49
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0200
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

CV Sciences, Inc. engages in the development, manufacture, marketing, and sale of herbal supplements, hemp-based cannabidiol (CBD), and plant-based food products in North America. It offers its products under the PlusCBD, PlusCBD Pet, PlusHLTH, Cultured Foods, and Lunar Fox brand names in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, select distributors, brick and mortar retailers, and select e-tailers. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

www.cvsciences.com

42

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 9/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CVSI
66.83%
S&P 500 (^GSPC)
11.99%

1-Year Return

CVSI
50.25%
S&P 500 (^GSPC)
19.50%

3-Year Return

CVSI
50.25%
S&P 500 (^GSPC)
69.77%

5-Year Return

CVSI
92.89%
S&P 500 (^GSPC)
68.98%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY22
Revenue 3.75M
Earnings -1.03M
Profit Margin -27.49%

Q4

FY21

Q1

FY22

Q2

FY22

Q3

FY22

-5M
0
-150.0%
-100.0%
-50.0%

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    4.52M

  • Enterprise Value

    5.50M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.30

  • Price/Book (mrq)

    2.87

  • Enterprise Value/Revenue

    0.43

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -15.74%

  • Return on Assets (ttm)

    -8.37%

  • Return on Equity (ttm)

    -118.91%

  • Revenue (ttm)

    12.74M

  • Net Income Avi to Common (ttm)

    -2.01M

  • Diluted EPS (ttm)

    -0.0200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    266k

  • Total Debt/Equity (mrq)

    79.76%

  • Levered Free Cash Flow (ttm)

    70.12k

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: